29,392 Shares in DaVita Inc. $DVA Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new stake in shares of DaVita Inc. (NYSE:DVA) in the second quarter, HoldingsChannel.com reports. The fund acquired 29,392 shares of the company’s stock, valued at approximately $6,539,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Root Financial Partners LLC boosted its position in shares of DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares during the last quarter. Caitlin John LLC bought a new stake in DaVita in the 4th quarter valued at $34,000. Sankala Group LLC purchased a new stake in DaVita in the 4th quarter worth $39,000. Canada Pension Plan Investment Board purchased a new stake in DaVita in the 2nd quarter worth $43,000. Finally, Kestra Advisory Services LLC bought a new position in shares of DaVita during the 4th quarter valued at about $45,000. Institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

NYSE:DVA opened at $180.72 on Monday. The firm has a market capitalization of $11.53 billion, a price-to-earnings ratio of 14.79, a PEG ratio of 0.47 and a beta of 0.88. The business has a 50 day simple moving average of $211.96 and a 200-day simple moving average of $183.37. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.DaVita’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts expect that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. TD Cowen raised DaVita from a “hold” rating to a “buy” rating and lifted their target price for the stock from $201.00 to $220.00 in a report on Friday, August 7th. Truist Financial cut their price target on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Raymond James Financial set a $220.00 target price on DaVita in a research report on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $265.00 price target on shares of DaVita in a research report on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $221.75.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.90% of the company’s stock.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.